Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CoLucid Hopes Lasmiditan Can Offer New, Safer Migraine Drug Class

Executive Summary

Prospects that CoLucid Pharmaceuticals’ lead asset might offer a viable new class of migraine treatment are brighter following the release of positive Phase III data showing lasmiditan helps twice as many patients to be headache-free after two hours versus a placebo.

You may also be interested in...



Lilly's Lasmiditan NDA Review Could Hinge On US FDA's Migraine Guidance

Potential first-in-class on-demand oral migraine treatment would complement new prevention products from Lilly, Amgen and Teva. 

Phase III Lasmiditan Data Strengthens Lilly's Dual Migraine Strategy

Lilly will submit lasmiditan for FDA approval after a second positive Phase III study, giving the company a product to stop migraine when its galcanezumab isn't able to prevent the headaches.

Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m

In acquiring biotech CoLucid and its Phase III acute migraine candidate lasmiditan for $960m, Lilly gets back an asset it discovered and out-licensed more than a decade ago. The pharma hopes to pair the 5-HT1F agonist with galcanezumab to create a two-drug migraine franchise.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel